Fatal ventricular arrhythmia
Conditions
Interventions
Implantable cardioverter-defibrillator transplantation is performed for fatal ventricular arrhythmia, and iATP and conventional ATP are performed in the treatment.
Sponsors
Yoshihisa Naruse
MEDTRONIC JAPAN CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients over 20 years old 2. Patients diagnosed with persistent ventricular tachycardia due to organic heart disease and scheduled to undergo electrophysiological examination and catheter ablation for therapeutic purposes 3. Patients who are scheduled to undergo or have already been implanted with an implantable cardioverter-defibrillator (Medtronic Cobalt XT) transplantation prior to ablation treatment
Exclusion criteria
Exclusion criteria: 1. Patients less than 3 months after the onset of myocardial infarction 2. Patients who are dependent on catecholamines 3. Patients who are judged to be inappropriate for registration in this study by the investigator and the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validity of iATP settings automatically calculated by ICD | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The following comparison between the conventional ATP group and the iATP group (details of the success rate of ventricular tachycardia arrest by A-1 ATP and the failure of ventricular tachycardia arrest by A-2 ATP [increased heart rate of ventricular tachycardia, ventricular fibrillation] Activation, reinduction after VT stop, Pacing non capture, unsuccessful entry into VT circuit, unsuccessful entry into Termination zone]) 2) Detailed examination of the intracardiac potential when VT is stopped (excitation propagation time, etc.) 3) Examination of predictors of success / failure in the first treatment 4) Examination of predictors of success / failure in treatment up to the final sequence | — |
Contacts
Public ContactNaruse Yoshihisa
Hamamatsu University School of Medicine
Outcome results
None listed